Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand  by Chotpitayasunondh, Tawee et al.
Vaccine 35 (2017) 299–304Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc inePost-licensure, phase IV, safety study of a live attenuated Japanese
encephalitis recombinant vaccine in children in Thailandqhttp://dx.doi.org/10.1016/j.vaccine.2016.11.062
0264-410X/ 2016 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
q Data previously presented: T. Chotpitayasunondh et al. 2016 Abs ESPID, Brighton, UK: ESP16-0414 (http://espid2016.kenes.com/Documents/ESPID16_Abstrac
⇑ Corresponding author at: Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
E-mail address: pkosalaraksa@yahoo.com (P. Kosalaraksa).Tawee Chotpitayasunondh a, Pornpimol Pruekprasert b, Thanyawee Puthanakit c,d, Chitsanu Pancharoen c,
Auchara Tangsathapornpong e, Peninnah Oberdorfer f, Pope Kosalaraksa g,⇑, Olarn Prommalikit h,
Suwimon Tangkittithaworn i, Phirangkul Kerdpanich j, Chonnamet Techasaensiri k, Joanna Korejwo l,
Sunate Chuenkitmongkol m, Guy Houillon l
aQueen Sirikit National Institute of Child Health (Children’s Hospital), Bangkok, Thailand
bDepartment of Pediatrics, Faculty of Medicine, Songklanagarind Hospital, Prince of Songkla University, Songkhla, Thailand
cDepartment of Pediatrics, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
dResearch Unit in Pediatric Infectious Diseases and Vaccines, Chulalongkorn University, Bangkok, Thailand
eDepartment of Pediatrics, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
fDivision of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
gDepartment of Pediatrics, Faculty of Medicine, Srinagarind Hospital, Khon Kaen, Thailand
hHRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University, Nakornnayok, Thailand
iDepartment of Pediatrics, Chonprathan Hospital, Srinakharinwirot University, Nonthaburi, Thailand
jDivision of Infectious Diseases, Department of Pediatrics, Phramongkutklao Hospital, Bangkok, Thailand
kDepartment of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
l Sanofi Pasteur, Lyon, France
m Sanofi Pasteur, Bangkok, Thailand
a r t i c l e i n f o a b s t r a c tArticle history:
Received 14 September 2016
Received in revised form 16 November 2016
Accepted 17 November 2016
Available online 28 November 2016
Keywords:
Japanese encephalitis
Vaccine
JE-CV
Safety
Primary
BoosterBackground: Japanese encephalitis is a mosquito-borne viral disease endemic in most countries in Asia. A
recombinant live, attenuated Japanese encephalitis virus vaccine, JE-CV, is licensed in 14 countries,
including Thailand, for the prevention of Japanese encephalitis in adults and children.
Methods: This was a prospective, phase IV, open-label, multicentre, safety study of JE-CV conducted from
November 2013 to April 2015, to evaluate rare serious adverse events (AEs). JE-CV was administered to
10,000 healthy children aged 9 months to <5 years in Thailand as a primary (Group 1) or booster (Group
2) vaccination. Serious AEs (SAEs), including AEs of special interest, up to 60 days after administration
were evaluated. Immediate Grade 3 systemic AEs up to 30 min after JE-CV administration were also
described.
Results: The median age of participants was 1.1 years in Group 1 and 3.8 years in Group 2. SAEs were
reported in 204 (3.0%) participants in Group 1 and 59 (1.9%) participants in Group 2. Among a total of
294 SAEs in 263 participants, only three events occurring in two participants were considered related
to vaccination. All three cases were moderate urticaria, none of which met the definition of AEs of special
interest for hypersensitivity. AEs of special interest were reported in 28 (0.4%) participants in Group 1 and
4 (0.1%) participants in Group 2; none were considered related to vaccination. Febrile convulsion was the
most frequently reported AE of special interest: 25 (0.4%) participants in Group 1; and 2 (<0.1%) in Group
2. There were no cases of Japanese encephalitis reported. No Grade 3 immediate systemic AEs were
reported after any JE-CV vaccination.
Conclusions: Our study did not identify any new safety concerns with JE-CV and confirms its good safety
profile.
This study was registered on www.clinicaltrials.gov (NCT01981967; Universal Trial Number: U1111-
1127-7052).
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ts.pdf).
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Japanese encephalitis (JE) is a mosquito-borne viral disease that
is endemic in most countries in Asia [1]. JE belongs to the same
genus (Flavivirus) as yellow fever (YF) and dengue viruses [2].
The greatest burden of disease occurs in childhood with 66% of
cases occurring in those under 15 years of age and an overall case
fatality rate of up to 35% [3]. In Thailand during the 1970s and
1980s, 1500–2500 cases of encephalitis were reported annually
[3]; following the introduction of a national JE vaccination pro-
gramme in 1990, the number of cases declined to 297–418 cases
per year between 2002–2008, reflecting the large proportion of
cases caused by JE virus [4].
There is no specific antiviral treatment for JE. The World Health
Organization recommends that JE vaccination should be integrated
into national immunisation schedules in endemic areas [5]. A live,
attenuated JE vaccine (JE-CV; IMOJEVTM, Sanofi Pasteur) has been
developed using the YF virus vaccine vector YF17D with the cDNA
encoding the envelope proteins of YF virus replaced with that of
the attenuated JE SA-14-14-2 virus strain [6,7]. A number of phase
II and phase III studies conducted in adults and children have
demonstrated the safety and immunogenicity of JE-CV [5,8–13].
The vaccine was first registered in Australia and Thailand in 2010
in children aged 12 months to 5 years and has subsequently been
licensed in 12 other countries to date, for the prevention of JE in
both children and adults. For children, the current recommended
dosing schedule for JE-CV is a single dose as primary vaccination
from 9 months of age followed by a booster dose 12–24 months
later [14]. In adults, a booster dose is not required for up to 5 years
after administration of a single dose of JE-CV [14].
Previous safety evaluation in non-clinical studies showed no
evidence of viscerotropism or neurotropism [15]. We undertook
this large prospective phase IV post-marketing safety study to fur-
ther characterise the safety profile of JE-CV to evaluate rare
(>1/10,000 and <1/1000) serious adverse events (SAEs) in a large
population. Here we describe Grade 3 systemic immediate adverse
events (AEs) and SAEs, including AEs of special interest (AESIs), of
JE-CV following administration to 10,000 children, 70% of whom
received JE-CV for the first time.2. Methods
2.1. Study design
This study was a prospective, phase IV, open-label, multicentre,
safety study of the live attenuated JE vaccine, JE-CV, administered
to 10,000 healthy children in Thailand either as a primary vaccina-
tion (Group 1) or as a booster 1 year after primary immunizaton
with inactivated JE vaccine or JE-CV (Group 2). The study was con-
ducted between 03 November 2013 and 09 April 2015 in accor-
dance with the ethical principles of the Declaration of Helsinki
and the International Conference on the Harmonization-Good Clin-
ical Practice guidelines. In addition, the study protocol, including
any amendments, was approved by each study site’s Institutional
Review Board and Independent Ethics Committee. Written
informed consent was obtained from the parents/guardians of all
children before study entry. This trial has been registered at
www.clinicaltrials.gov (identifier NCT01981967; Universal Trial
Number: U1111-1127-7052).
At study initiation, children aged 12 months to less than 5 years
were eligible for inclusion, however, this criteria was later modi-
fied in 2014 to include children from 9 months of age, following
a change in the age indication for JE-CV. Participants were physi-
cally examined to assess general health at the time of inclusion;all participants required vaccination against JE. Children who had
received medications such as high dose systemic corticosteroids,
antiviral drugs, immunosuppressive drugs (usually chemotherapy)
and immunoglobulins/blood products containing immunoglobu-
lins within the last three months were excluded. Other exclusion
criteria included: any contraindications to JE-CV vaccination, par-
ticipation in another clinical trial in the four weeks preceding the
vaccination or at any time during the study period, a medical pro-
cedure or receipt of any vaccine in the four weeks preceding the
study vaccination, planned vaccination in the four weeks following
the study vaccination, previous vaccination with another live
attenuated JE vaccine (CD-JEVAX, Chengdu Institute of Biological
Products, Chengdu, China) or prior receipt of JE-CV earlier in this
study as primary vaccination (Group 2 only).
The proportions of participants included in the study to receive
JE-CV either as primary vaccination (Group 1) or as a booster
(Group 2) were approximately 70% and 30%, respectively. Group
1 was defined as follows: participants who never received a JE vac-
cine; participants who received a single dose of inactivated JE vac-
cine; and participants whose JE vaccination history was unknown
or not documented. Group 2 was defined as follows: participants
who received at least 2 doses of inactivated JE vaccine (at least
1 year earlier since the last dose); participants who received a sin-
gle dose of JE-CV as part of the routine vaccination schedule at least
1 year earlier.
2.2. Vaccine
The JE-CV vaccine (IMOJEVTM, Sanofi Pasteur) was supplied as
powder and solvent for injection. The solvent for reconstitution
consisted of sterile 0.4% sodium chloride solution. Two batches of
JE-CV (batch numbers 08A1201BF and 08A1305BB) were used in
the study. Each 0.5 mL dose of reconstituted vaccine contained
4.0 (batch 08A1201BF) or 5.8 log10 (batch 08A1305BB) plaque
forming units of lyophilised vaccine virus. The vaccine was admin-
istered subcutaneously into the anterolateral aspect of the thigh or
the deltoid region of the upper arm.
2.3. Safety
Participants were kept under observation for 30 min after
vaccination to monitor the appearance of any immediate Grade 3
systemic AE. Systemic reactions were graded as follows: for fever,
Grade 3 AEs were defined as a body temperature >39.5 C for
participants aged <2 years or P39.0 C for participants aged
P2 years. For any other AE, Grade 3 was defined as a significant
AE that prevents normal activity.
Parents/guardians were provided with cards to record
information and events during the 60-day follow-up period.
Parents/guardianswere interviewed by telephone on four occasions
during the 60-day follow-upperiod using a questionnaire to capture
SAEs (including AESIs); relevant information was transcribed onto
case report forms. A SAE was defined as any untoward medical
occurrence following the dose (including overdose) that: resulted
in death; was life-threatening; required inpatient hospitalisation
or prolongation of existing hospitalisation; resulted in persistent
or significant disability/incapacity; was a congenital anomaly/birth
defect; or was an important medical event. AESIs were selected
based on events previously reported with licensed JE mouse-brain
derived vaccines and related YF17D vaccines, or events typically
expected after vaccination with a live-attenuated vaccine. These
included: hypersensitivity reactions (severe [Grade 3] allergic reac-
tion, regardless of the relationship to the vaccine, anaphylactic/ana-
phylactoid reaction); neurological disorders such as convulsions
Table 1
Baseline characteristics of participants.
Group 1 (N = 6851) Group 2 (N = 3149)
Sex: n (%)
Male 3530 (51.5) 1599 (50.8)
Female 3321 (48.5) 1550 (49.2)
Sex ratio: Male/Female 1.1 1.0
Age (year)
Median 1.1 3.8
Min; Max 0.7; 5.0 1.0; 5.1
Age classification: n (%)
<1 year 1750 (25.5) 0 (0.0)
P1 and <2 years 4807 (70.2) 22 (0.7)
P2 years 294 (4.3) 3127 (99.3)
Weight (kg)
Mean (SD) 9.8 (1.9) 15.5 (3.6)
Min; Max 5.5; 38.0 8.3; 49.0
Max: maximum; Min: minimum; N: number of participants who received the study
vaccine; n: number of participants with characteristic; SD: standard deviation.
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such as encephalopathy, encephalitis, acute disseminated
encephalomyelitis, myelitis, Guillain-Barré syndrome, peripheral
neuropathy, facial (Bell’s) palsy; and laboratory-confirmed vaccina-
tion failure (JE after JE-CV vaccination). Guidelines andBrightonCol-
laboration case definitions were provided to the Investigator to
assist in the assessment of AEs that may have been suggestive of a
viscerotropic or neurotropic disease. Parents were instructed to
inform the study site and to bring the participant for anunscheduled
visit if the participant developed severe fever.
In the event of severe (Grade 3) fever of unknown etiology on at
least two consecutive days within 14 days after vaccination,
viremia assessments for JE and dengue were undertaken using JE
virus isolation techniques. Briefly, laboratory-reared mosquitoes,
Toxorhynchites splendens, aged 2–4 days, were inoculated intratho-
racically with the participant’s sera. After incubation for 14 days at
32 C, the presences of viral antigens was determined by direct
fluorescence assay using fluorescein isothiocyanate conjugate
anti-flavivirus antibodies. Identification of virus type was con-
firmed by indirect fluorescence assay.
The site Investigator assessed the causal relationship between
each SAE (including AESI) and vaccination as either not-related
or related. An AE was defined as not-related when it was clearly
or most probably caused by other etiologies such as the partici-
pant’s underlying condition, therapeutic intervention, or concomi-
tant therapy or the delay between vaccination and the onset of the
AE was incompatible with a causal relationship. An AE was defined
as related when there was a reasonable possibility that the AE was
caused by the vaccination, meaning that there was evidence or
arguments to suggest a causal relationship.2.4. Statistical analysis
The sample size was selected to allow the detection of rare AEs
with a frequency >1/10,000 and <1/1000 (>0.01% and <0.1%). The
10,000 participants included in the study provided a probability
of approximately 95% of observing any AE with a true frequency
of 1/3333. All participants who received JE-CV either as a primary
dose or as a booster dose were included in the safety analysis set.
No hypothesis testing was performed in this study. Grade 3
immediate systemic AEs and SAEs (including AESIs) occurring up
to Day 60 were summarised in terms of the number and percent-
age of participants experiencing these events, with participants
receiving JE-CV as primary vaccination or as a booster dose sum-
marised separately. For the main parameters, 95% confidence inter-
vals (CIs) of percentages were calculated using the exact binomial
distribution for proportions (Clopper-Pearson method) [16].3. Results
3.1. Study population
10,000 participants received JE-CV either as a primary dose
(6851 participants) or as a booster dose (3149 participants) during
the study period. There were 28 (0.3%) participants who did not
meet all inclusion criteria or met the exclusion criteria; nine had
participated in another clinical trial in the four weeks preceding
the vaccination; 14 received a vaccine in the four weeks following
the study vaccination; four were not aged 9 months to less than
5 years on the day of inclusion; and one had been previously vac-
cinated with CD-JEVAX. These participants were not withdrawn
but continued to participate in the study and were included in
the safety analysis set. 9965 (99.7%) participants completed the
trial (up to 60 days after the vaccination). 35 (0.4%) participants
withdrew from the trial; 20 voluntarily withdrew from the studyfor reasons unrelated to AEs, 14 were lost to follow-up and one
participant died from leukaemia (unrelated to the administered
vaccine).
Participant characteristics, measured at baseline (Study Day 0),
are summarised in Table 1. At enrolment, the median age of partic-
ipants in Group 1, who received a primary vaccination with JE-CV,
was 1.1 years which was younger than participants in Group 2 who
had a median age of 3.8 years. As the participants in Group 2 were
older than in Group 1, they also had a higher body mass (mean
15.5 kg versus 9.8 kg). There were slightly more male participants
than female participants at enrolment (51.5% versus 48.5% in
Group 1, and 50.8% versus 49.2% in Group 2).
3.2. Safety
There were no Grade 3 immediate (within 30 min) systemic AEs
reported after any JE-CV vaccination. A summary of the most fre-
quent and related SAEs (including AESIs) within 60 days after
administration of JE-CV is provided in Table 2. A total of 231 SAEs
were experienced by 204 (3.0%) participants after JE-CV primary
vaccination (Group 1), and 63 SAEs were experienced by 59
(1.9%) participants after JE-CV booster vaccination (Group 2).
Three SAEs (including AESIs), reported in 2 participants in
Group 1, were considered related to vaccination by the Investiga-
tor. One participant developed urticaria 4 h after receiving JE-CV
and recovered 2 days later. The other participant experienced 2
events of urticaria (2 days after vaccination, lasting 7 days, and
16 days after vaccination, lasting 5 days). The three events were
considered as moderate hypersensitivity which did not lead to hos-
pitalisation, and therefore did not meet the case definition of AESI
limited to severe (Grade 3) or serious (hospitalised)
hypersensitivity.
Table 3 summarises the AESIs reported within 60 days after
vaccination with JE-CV. There were no AESIs that were considered
related to vaccination by the Investigator. Febrile convulsion was
the most frequently reported AESI, occurring mainly in Group 1
(Table 3). 20 of 27 participants reporting febrile convulsion had
an alternative etiology (pneumonia, influenza, bacterial pharyngi-
tis or other infections). In the remainder, the time to onset of feb-
rile convulsion was not consistent with a potential role of
administered vaccine. Indeed, there was an equal distribution of
febrile convulsions throughout the 60-day study period (Fig. 1).
Two participants had blood samples taken for assessment of JE,
and dengue viremia and were confirmed to have viral pneumonia
and viral nasopharyngitis. There were no cases of JE reported. In
addition, a single episode of convulsion without fever was reported
Table 2
Most frequent serious adverse events within 60 days after vaccine injection.
Group 1 (N = 6851) Group 2 (N = 3149)
All SAEs Related SAEs All SAEs Related SAEs
n % (95% CI) n SAEs n % (95% CI) n SAEs n % (95% CI) n SAEs n % (95% CI) n SAEs
Participants experiencingP 1:
SAE 204 3.0 (2.6; 3.4) 231 2 <0.1 (0.0; 0.1) 3 59 1.9 (1.4; 2.4) 63 0 0.0 (0.0; 0.1) 0
Infections and infestations 161 2.4 (2.0; 2.7) 174 0 0.0 (0.0; 0.1) 0 46 1.5 (1.1; 1.9) 47 0 0.0 (0.0; 0.1) 0
Gastroenteritis 28 0.4 (0.3; 0.6) 29 0 0.0 (0.0; 0.1) 0 8 0.3 (0.1; 0.5) 8 0 0.0 (0.0; 0.1) 0
Pneumonia 24 0.4 (0.2; 0.5) 24 0 0.0 (0.0; 0.1) 0 7 0.2 (0.1; 0.5) 7 0 0.0 (0.0; 0.1) 0
Bronchitis 17 0.2 (0.1; 0.4) 17 0 0.0 (0.0; 0.1) 0 10 0.3 (0.2; 0.6) 10 0 0.0 (0.0; 0.1) 0
Pneumonia viral 10 0.1 (0.1; 0.3) 11 0 0.0 (0.0; 0.1) 0 1 <0.1 (0.0; 0.2) 1 0 0.0 (0.0; 0.1) 0
Pharyngitis 10 0.1 (0.1; 0.3) 10 0 0.0 (0.0; 0.1) 0 0 0.0 (0.0; 0.1) 0 0 0.0 (0.0; 0.1) 0
Influenza 4 <0.1 (0.0; 0.1) 4 0 0.0 (0.0; 0.1) 0 5 0.2 (0.1; 0.4) 5 0 0.0 (0.0; 0.1) 0
Nervous system disorders* 28 0.4 (0.3; 0.6) 31 0 0.0 (0.0; 0.1) 0 2 <0.1 (0.0; 0.2) 2 0 0.0 (0.0; 0.1) 0
Febrile convulsion 25 0.4 (0.2; 0.5) 28 0 0.0 (0.0; 0.1) 0 2 <0.1 (0.0; 0.2) 2 0 0.0 (0.0; 0.1) 0
Gastrointestinal disordersy 18 0.3 (0.2; 0.4) 18 0 0.0 (0.0; 0.1) 0 6 0.2 (0.1; 0.4) 6 0 0.0 (0.0; 0.1) 0
Diarrhoea 8 0.1 (0.1; 0.2) 8 0 0.0 (0.0; 0.1) 0 0 0.0 (0.0; 0.1) 0 0 0.0 (0.0; 0.1) 0
Gastritis 8 0.1 (0.1; 0.2) 8 0 0.0 (0.0; 0.1) 0 4 0.1 (0.0; 0.3) 4 0 0.0 (0.0; 0.1) 0
N: number of participants who received the study vaccine; n: number of participants experiencing the endpoint; n SAEs: number of SAEs.
Group 1: participants received JE-CV as a primary vaccination; Group 2: participants received JE-CV as a booster vaccination. CI: Confidence interval; SAEs: serious adverse
events.
* Nervous system disorders, other than febrile convulsions, included convulsion without fever (n = 1) and epilepsy (n = 2), which were reported only in Group 1.
y Gastrointestinal disorders, other than diarrhoea and gastritis, included enteritis (n = 1) and mouth ulceration (n = 1) in Group1; and dyspepsia (n = 1) and food poisoning
(n = 1) in Group 2.
Table 3
Adverse events of special interests within 60 days after vaccine injection.
Group 1 (N = 6851) Group 2 (N = 3149)
n % (95% CI) Number of AESIs n % (95% CI) Number of AESIs
Participants experiencingP 1:
AESI 28 0.4 (0.3; 0.6) 31 4 0.1 (0.0; 0.3) 4
Nervous system disorder 28 0.4 (0.3; 0.6) 31 2 <0.1 (0.0; 0.2) 2
Febrile convulsion 25 0.4 (0.2; 0.5) 28 2 <0.1 (0.0; 0.2) 2
Convulsion 1 <0.1 (0.0; 0.1) 1 0 0.0 (0.0; 0.1) 0
Epilepsy 2 <0.1 (0.0; 0.1) 2 0 0.0 (0.0; 0.1) 0
Skin and subcutaneous tissue disorder 0 0.0 (0.0; 0.1) 0 2 <0.1 (0.0; 0.2) 2
Urticaria 0 0.0 (0.0; 0.1) 0 2 <0.1 (0.0; 0.2) 2
AESIs: adverse events of special interest; CI: Confidence interval; N: number of participants who received the study vaccine; n: number of participants experiencing the
endpoint.
Group 1: participants received JE-CV as a primary vaccination; Group 2: participants received JE-CV as a booster vaccination.
Fig. 1. Distribution of febrile convulsions by days post-vaccination. Data show the distribution of febrile convulsions in group 1 (28 events) and group 2 (2 events). *Group 2
events (33 and 58 days post-vaccination, respectively).
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(Grade 3) or serious (hospitalised) urticaria was reported by 2
participants in Group 2, with a latency of 24 and 28 days after
vaccination, respectively. Two cases of epilepsy were reported
during the study; both in Group 1, with a latency of 20 and 28 days
after vaccination. No cases suggestive of vaccine-associated
neurotropic or viscerotropic diseases were reported during the trial
for either group.One death was reported during the study but was not consid-
ered related to vaccination: a 24-month-old male participant
developed fever, cough and runny nose and was diagnosed with
pharyngitis 2 days after receiving JE-CV as a booster vaccination.
Four days later the fever persisted and petechiae appeared. The
participant was admitted to the hospital and diagnosed with acute
myeloid leukaemia. The participant died from pulmonary
haemorrhage 3 days after admission. Blood samples to assess
T. Chotpitayasunondh et al. / Vaccine 35 (2017) 299–304 303vaccine viraemia were not taken during hospitalisation and there
were no remaining samples available for additional tests. An
autopsy was not performed, as requested by the participant’s fam-
ily. High level abnormalities in blood counts discovered 6 days
after vaccination suggested that the leukemia had been evolving
for several weeks before vaccination.4. Discussion
This phase IV post-marketing study was designed to further
characterise the safety profile of JE-CV, with an objective of identi-
fying any rare AEs. It is the largest study to date to assess the safety
profile of JE-CV. Although the sample size of this study was large
enough (n = 10,000) to detect rare events, no new risks were iden-
tified. Among 294 SAEs reported in 263 participants, only three
cases of moderate urticaria reported in two participants were con-
sidered related to vaccination. Furthermore, no Grade 3 immediate
systemic AEs were reported in the current study after vaccination
with JE-CV as a primary dose or as a booster dose.
Since JE-CV is a chimeric vaccine with a YF17D vaccine virus
backbone and antigenic determinants of a live, attenuated JE vac-
cine strain, we selected AESIs to be monitored in our study based
on events that have already been reported following vaccination
with licensed JE mouse-brain derived and YF17D vaccines, and
events typically expected after vaccination with a live-attenuated
vaccine. Events meeting AESI definitions were classified as such,
irrespective of the relationship to the vaccine. In our study, overall
rates of AESI were very low and no AESI was considered related to
vaccination. The most frequently reported AESI was febrile convul-
sion, mainly following primary JE-CV vaccination. The rate of feb-
rile convulsions (0.4%) in the current study following
administration of JE-CV as a primary vaccination was similar to
that observed in another study (0.3%) where JE-CV was adminis-
tered as a primary dose to toddlers aged 12–18 months in Asia
[10]. Post-marketing surveillance studies of other live attenuated
JE vaccines reported similar rates of febrile convulsions (0.33%)
[17] and urticaria (0.2%) [18], as observed in the current study. Feb-
rile convulsions are also associated with other live and inactivated
vaccines [19]. However, it should be noted that febrile convulsions
are common in childhood in the absence of vaccination, affecting
2–5% of children less than 5 years of age, with a peak incidence
at approximately 18 months of age [20]. Moreover, febrile convul-
sions have been reported to occur more frequently in children in
Asian countries [20].
A total of two cases of epilepsy were reported during the study;
both occurred in children less than 1 year of age. Although previ-
ous concerns of a possible association between vaccination and
epileptic seizures have caused controversy in the literature, epi-
demiological evidence does not support a causal relationship
between vaccination and childhood epilepsy [21,22]. The World
Health Organization reports the incidence of epilepsy to be
25–840 cases per 100,000 children annually, with a higher inci-
dence in developing countries than in industrialized countries
[23]. Age-specific incidence of epilepsy is consistently high in the
youngest age groups, with highest incidence occurring during the
first year of life [24]. As the current trial included 10,000 partici-
pants followed for 2 months, the expected number of epilepsy
cases derived from background incidence was between 0.4 and
14; therefore, the reported incidence of epilepsy in the current
study is within the expected background range. In addition, the
time to onset (20 days and 28 days for the two cases in our study)
was beyond the usual risk window for AEs related to live attenu-
ated vaccines.
One of the main strengths of the current study is its large sam-
ple size, enabling the detection of rare AEs with a frequency as lowas 1/3333. In addition, all participants in our study were actively
monitored to capture all serious adverse events, in contrast to
some post-marketing studies that rely on voluntary reporting of
events by patients and healthcare professionals. Our study
included participants aged 9 months to <5 years of age living in
Thailand, however, it is not known how generalisable our study
findings are to other age groups and geographic locations. It should
also be noted that, although unlikely in participants of a young age,
we cannot rule out a possible impact of prior exposure to dengue
virus or other flavivirus on the safety profiles observed for these
children.
In conclusion, our study did not reveal any new safety concerns
following primary or booster vaccination with JE-CV, confirming its
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